Skip to content Search the desk⌘ Ctrl K Agent Sign in G Gain Therapeutics, Inc.
G GANX Gain Therapeutics, Inc.
G GANX Gain Therapeutics, Inc.
Earnings When Gain Therapeutics, Inc. reports, what it reported each quarter, and how the stock took the results.
27 quarters. Mar 31, 2020 to Sep 30, 2026. USD.
Next results · Q4 2026 Projected
Mar 25, after the close
Thu, Mar 25, 2027 in 126 days
Projected from its last 8 releases. The company has not named the day yet.
Quarter Q4 2026 · Ends about Dec 31, 2026
10-K window Mar 22 – 30 Quarter by quarter 3 years 5 years 10 years
Revenue Net income EPS Operating income Operating cash flow Free cash flow
Q4 2023 · derived $ 0 . 0 0 $0.00 No Q4 2022 on file
Gain Therapeutics, Inc. · CIK 1819411 · Engraved from SEC EDGAR
Aug 11, 2026, after the close
Revenue — —
Net income -$4.68M N/M
EPS -$0.11 N/M
Revenue — —
Net income -$5.61M N/M
EPS -$0.13 N/M
Revenue — —
Net income -$4.54M N/M
EPS — —
Results day Typical move ±2.7% A typical move of 2.7% either way
Up after 5 of 12, down after 6.
−5.0% −0.8% +1.0%
When it reports
Usual day Varies
After quarter end 41 to 85 days
10-Q filed 41 to 44 days over its last 8
10-K filed 82 to 86 days over its last 5 ended Sep 30, 2024 · filed Nov 14, 2024 · 45 d ended Dec 31, 2024 · filed Mar 27, 2025 · 86 d ended Mar 31, 2025 · filed May 14, 2025 · 44 d ended Jun 30, 2025 · filed Aug 12, 2025 · 43 d ended Sep 30, 2025 · filed Nov 12, 2025 · 43 d ended Dec 31, 2025 · filed Mar 26, 2026 · 85 d FY 2026 Q3 2026 Sep 30, 2026 Nov 10, 2026 · after-hours Nov 10, 2026 41 d 10-Q — — -$0.07 0.0% Q2 2026 Jun 30, 2026 Aug 11, 2026 · after-hours Aug 11, 2026 42 d 10-Q — — -$0.11 +3.4% Q1 2026 Mar 31, 2026 May 11, 2026 · after-hours May 11, 2026 41 d 10-Q — — -$0.13 1.1%
FY 2025 Q4 2025 derived Dec 31, 2025 Mar 26, 2026 · after-hours Mar 26, 2026 85 d 10-K — — — 3.7% Q3 2025 Sep 30, 2025 Nov 12, 2025 · after-hours Nov 12, 2025 43 d 10-Q — — -$0.15 +1.2% Q2 2025 Jun 30, 2025 Aug 12, 2025 · after-hours Aug 12, 2025 43 d 10-Q — — -$0.19 +1.9% Q1 2025 Mar 31, 2025 May 14, 2025 · after-hours May 14, 2025 44 d 10-Q — — -$0.16 3.7%
FY 2024 Q4 2024 derived Dec 31, 2024 Mar 27, 2025 · after-hours Mar 27, 2025 86 d 10-K — — — 8.1% Q3 2024 Sep 30, 2024 Nov 14, 2024 · after-hours Nov 14, 2024 45 d 10-Q — — -$0.17 +7.2% Q2 2024 Jun 30, 2024 Aug 8, 2024 · after-hours Aug 8, 2024 39 d 10-Q — — -$0.42 +1.0% Q1 2024 Mar 31, 2024 May 14, 2024 · after-hours May 14, 2024 44 d 10-Q — — -$0.22 —
FY 2023 Q4 2023 derived Dec 31, 2023 Mar 26, 2024 · after-hours Mar 26, 2024 86 d 10-K $0.00 — — 0.8% Q3 2023 Sep 30, 2023 Nov 14, 2023 · after-hours Nov 14, 2023 45 d 10-Q $0.00 — -$0.37 — Q2 2023 Jun 30, 2023 Aug 10, 2023 · after-hours Aug 10, 2023 41 d 10-Q $0.00 −100.0% -$0.62 — Q1 2023 Mar 31, 2023 May 12, 2023 · pre-market May 12, 2023 42 d 10-Q $55.18K +47.0% -$0.43 —
FY 2022 Q4 2022 derived Dec 31, 2022 Mar 23, 2023 · after-hours Mar 23, 2023 82 d 10-K $0.00 −100.0% — 5.0% Q3 2022 Sep 30, 2022 Nov 10, 2022 · after-hours Nov 10, 2022 41 d 10-Q $0.00 −100.0% -$0.38 — Q2 2022 Jun 30, 2022 Aug 8, 2022 · pre-market Aug 8, 2022 39 d 10-Q $95.10K +16.5% -$0.43 +0.5% Q1 2022 Mar 31, 2022 May 16, 2022 · after-hours May 16, 2022 46 d 10-Q $37.54K +612.4% -$0.28 —
FY 2021 Q4 2021 derived Dec 31, 2021 Mar 24, 2022 · pre-market Mar 25, 2022 84 d 10-K $31.07K +240.0% — 5.0% Q3 2021 Sep 30, 2021 Nov 12, 2021 · pre-market Nov 12, 2021 43 d 10-Q $15.97K +138.5% -$0.39 +12.8% Q2 2021 Jun 30, 2021 Aug 11, 2021 · after-hours Aug 12, 2021 43 d 10-Q $81.62K +1,180.7% -$0.30 — Q1 2021 Mar 31, 2021 May 10, 2021 · after-hours May 10, 2021 40 d 10-Q $5.27K −21.0% -$0.50 —
FY 2020 Q4 2020 derived Dec 31, 2020 — — — — $9.14K — — — Q3 2020 Sep 30, 2020 — — — — $6.70K — -$0.25 — Q2 2020 Jun 30, 2020 — — — — $6.37K — -$0.27 — Q1 2020 Mar 31, 2020 — — — — $6.67K — -$0.29 —
Earlier years, FY 2020 to FY 2023 The latest three years
Move: the stock from the last close before the release to the first close after it. Last sale prices: Data provided for free by IEX. By accessing or using IEX Historical Data, you agree to the IEX Historical Data Terms of Use.
10-Q
May 11, 2026
The same quarter a year earlier, the figures the next ones will be compared with. Thaler holds no estimates.
Year over year, last four quarters
Revenue — Revenue, change from a year earlier: Q4 2023 n/m, Q3 2023 n/m, Q2 2023 −100.0%, Q1 2023 +47.0% +47.0% −100.0% n/m n/m
Net income -$4.54M Net income, change from a year earlier: Q3 2026 n/m, Q2 2026 n/m, Q1 2026 n/m, Q4 2025 n/m n/m n/m n/m n/m
EPS — EPS, change from a year earlier: Q3 2026 n/m, Q2 2026 n/m, Q1 2026 n/m, Q3 2025 n/m n/m n/m n/m n/m 0.0% by the close of Nov 11
Thaler Research Engraved from SEC EDGAR © 2026 Thaler. All rights reserved. Last sale prices: Data provided for free by IEX. By accessing or using IEX Historical Data, you agree to the IEX Historical Data Terms of Use.
+3.4% by the close of Aug 12
ended Mar 31, 2026 · filed May 11, 2026 · 41 d ended Jun 30, 2026 · filed Aug 11, 2026 · 42 d ended Sep 30, 2026 · filed Nov 10, 2026 · 41 d window Mar 22 – 30 · projected The stock’s move from the last close before each release to the first close after it, over the last 12 releases. Largest: −8.1% after Q4 2024.
Last sale prices: Data provided for free by IEX. By accessing or using IEX Historical Data, you agree to the IEX Historical Data Terms of Use.
Provenance Data status and checks